GlassScriptPhysician profile
Rose Boscaino
NPI 1235615295
$2,370.35
in general payments reported to CMS, 2019-2025
20 companies · $442 in 2025
The $442 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $52.97 · 2022: $185 · 2023: $767 · 2024: $923 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,132.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $393.35 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $377.87 | 2023-2024 | Caplyta |
| Novo Nordisk INC | $258.74 | 2022-2024 | Wegovy, Rybelsus |
| Sanofi-Aventis U.S. LLC | $206.25 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $162.76 | 2022-2023 | Xarelto, Spravato |
| Neurocrine Biosciences, INC. | $125.23 | 2025 | |
| Kyowa Kirin, INC. | $120.17 | 2024 | Crysvita |
| Idorsia Pharmaceuticals US INC | $115.93 | 2023 | Quviviq |
| Silk Road Medical, INC. | $103.65 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Boston Scientific Corporation | $90.85 | 2025 | Enroute Transcarotid Neuroprotection System |
| Alexion Pharmaceuticals, INC. | $88.55 | 2024 | Ultomiris |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $75.59 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.93 | 2022 | |
| Medtronic, INC. | $46.63 | 2023 | Interstim |
| Eisai INC. | $36.35 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $33.06 | 2023 | Rexulti |
| Vanda Pharmaceuticals INC. | $23.93 | 2023 | Fanapt, Hetlioz |
| Novartis Pharmaceuticals Corporation | $16.62 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $16.27 | 2024 | Breztri |
| Amgen INC. | $14.62 | 2023 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Boscaino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.